BioCardia Reports Q3 2026 Financial Results and Regulatory Progress in Japan and U.S.
BioCardia (BCDA) reported a net loss of $1.8 million for the third quarter of 2026, consistent with the prior year's results. Despite the loss, the company improved its net loss per share to $0.12 from $0.24 in Q3 2025, aided by a higher weighted-average share count. As of September 30, 2026, the company holds $2.2 million in cash and cash equivalents, which management expects will provide an operational runway into 2027. The company is heavily focused on regulatory milestones for its CardiAMP cell therapy and Helix delivery system. In Japan, BioCardia has addressed all inquiries from the PMDA and is preparing for a Shonin submission, targeting an initial patient population of 20,000. In the United States, management is pursuing FDA approval for the Helix system via a de novo pathway, with a target approval date in mid-2027 based on clinical data from approximately 500 patients.
Topics: biotechnology clinical trials earnings report net loss regulatory approval